Urteste (WSE: URT) has announced that the United States Patent and Trademark Office (USPTO) granted a patent for Panuri, a non-invasive test for detecting pancreatic cancer.
According to Urteste, the Panuri test is also protected by patents in Poland, Japan, Indonesia, Singapore, Russia, and South Korea.
In a statement, Grzegorz Sefanski, co-founder and CEO of Urteste, commented, “Obtaining a patent in the U.S. is another significant step in building the value of the Panuri project. The United States is the world’s largest market for in vitro diagnostics, which is why effective intellectual property protection is crucial both for the project’s further development and for discussions with potential strategic partners. It also confirms the global innovation of our technology for detecting cancer based on a urine sample. Furthermore, we plan to seek patent protection for additional components of the Panuri test, which will expand the scope of protection and extend its duration. We have the world’s broadest portfolio of prototype oncological diagnostic tests based on urine sample analysis, and we are consistently implementing a strategy aimed at their commercialization.”
